Joe Ross is the new Vice President of U.S. Marketing at LDR Spine.
Ross to Lead LDR U.S. Marketing
1 min read Premium comments
Ross “will lead all aspects of commercial marketing and provide essential support for continue sales growth, ” according to the December 20 announcement.
Ross joins LDR during a time of growth and new product launches.
“The Vertebridge portfolio has been tremendously well received by the physician community and we will be releasing two new applications of the technology in the first half of 2011. LDR is also particularly well positioned as one of only two companies to complete both a one and two level concurrent cervical artificial disc IDE trial with two-year follow up, and Mobi-C may become a very important addition to the developing cervical arthroplasty market, ” said Ross.
Christoph Lavigne, LDR’s CEO said the company is experiencing “considerable” revenue growth in the U.S.
“It is critical that our organizational capabilities keep pace with our market presence, and Joe is uniquely qualified to lead our marketing efforts given his vast spine industry experience and knowledge. In addition, as we approach the upcoming review of the Mobi-C cervical artificial disc IDE clinical trial data by the FDA, Joe’s experience marketing PMA approved spine products will be of immense value, ” added Lavigne.
Ross comes to LDR from Axial Biotech, Inc., where he was Vice President of Strategic Initiatives.
Before that he spent more than 11 years at DePuy Spine where he was Worldwide Vice President of New Business Development. He is a graduate of the University of Notre Dame and Troy University, and served five years as an officer in the United Stated Navy.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.